At a glance
ClinicalIndex Comparison RecordPhase 3Active· 406 enrolled
Drug / intervention
sparsentan +2 moredrug
Likely dose
sparsentan 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
In Brief
A Phase 3 clinical trial evaluating sparsentan, irbesartan, and 1 other intervention for Immunoglobulin A Nephropathy. Active but no longer recruiting, targeting 406 participants across 162 sites in 18 countries.
Detailed Summary
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunoglobulin A Nephropathy
CountriesAustralia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Lithuania, New Zealand, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3ActiveOverdue
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartDec 2018
Primary CompletionAug 2023
Study CompletionJul 2026
TodayJul 2026
First PostedDec 4, 2018
Enrollment StartDec 11, 2018
Primary CompletionAug 7, 2023
Study CompletionJul 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 7.6 years ago
Interventions
sparsentandrug
Target dose of 400 mg daily
irbesartandrug
Target dose of 300 mg daily
Dapagliflozindrug
Target dose of 10 mg daily